British immersive technology company FourPlus has announced that it has secured funding from the UK’s national innovation agency, dubbed Innovate UK, to create a mixed reality training platform for pharmaceutical companies and the health sector.
FourPlus’ immersive technology, including its virtual reality experiences, is used in the life sciences industry for workforce management, 3D asset visualization for marketing and training purposes, plant visualization, lab training for bioscience students and data visualization.
Using a £1 million ($1.28 million) investment, the majority of which came from Innovate UK, FourPlus and its collaborators Holosphere and Cell and Gene Therapy Catapult, will develop a mixed reality experience with multiplayer capabilities for train individuals for manufacturing roles within the cell. and gene therapy and in the biopharmaceutical and broader life sciences sectors.
The platform will also help train staff, store digital training records, include data analysis tools and enable trainer/trainee collaboration in virtual environments.
Mixed Reality (MR) is an immersive computer-generated environment that combines the physical and digital worlds and allows physical and digital elements to interact.
FourPlus will build and deliver the platform over an 18-month period, and the first version of the offering will be available for demonstration by the end of 2023.
“We are really excited to start this innovative project with Holosphere and Cell and Gene Therapy Catapult. We already know that virtual reality is a powerful way to support the training of new employees in the sector, as it reduces costs, time, utilization and waste generation. This project will deliver the next-generation solution that integrates mixed reality, training personalization, multi-user interactivity, data analytics, and assistive features. training,” Dr. Ivan Wall, CEO of Four Plus, said in a statement.
THE GREAT TREND
Extended reality (i.e. virtual, augmented and mixed reality) is increasingly used in healthcare.
In December, based in Germany apoQlar announced it has received 510(k) clearance from the FDA for its VSI HoloMedicine platform, a mixed reality offering that helps surgeons plan procedures using 3D holographic technology.
Last month, augmented reality platform Augmedics secured $82.5 million in Series D funding to support the growth of its offerings, including its xvision Spine system, which uses augmented reality to give surgeons a 3D image of a patient’s spinal anatomy directly in their field of vision during surgery.
Other immersive technology companies include California-based virtual reality therapy company AppliedVRvirtual reality surgical training and assessment platform Osso VRvirtual reality digital therapy company focused on seniors MyndVRBoston-based virtual reality platform XRHealth and mental health platform in virtual and augmented reality Helium.